The lack of either IRF9 , or STAT2 , has surprisingly little effect on human natural killer cell development and function
Immunology · 2024
DOI: 10.1111/imm.13779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2024. Verfasst von Ane Calvo-Apalategi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Oncology, CNB-CSIC, Madrid, Spain. Hauptthemen laut MEDLINE: Killer Cells, Natural, STAT2 Transcription Factor, Interferon-Stimulated Gene Factor 3, gamma Subunit, Interferon Type I. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Carlos III Health Institute, Secretaría de Estado de Investigación, Desarrollo e Innovación, Spanish Association Against Cancer.
Abstract (Originalsprache)
Analysis of genetically defined immunodeficient patients allows study of the effect of the absence of specific proteins on human immune function in real‐world conditions. Here we have addressed the importance of type I interferon signalling for human NK cell development by studying the phenotype and function of circulating NK cells isolated from patients suffering primary immunodeficiency disease due to mutation of either the human interferon regulatory factor 9 (IRF9) or the signal transducer and activator of transcription 2 (STAT2) genes. IRF9, together with phosphorylated STAT1 and STAT2, form a heterotrimer called interferon stimulated gene factor 3 (ISGF3) which promotes the expression of hundreds of IFN‐stimulated genes that mediate antiviral function triggered by exposure to type I interferons. IRF9‐ and STAT2‐deficient patients are unable to respond efficiently to stimulation by type I interferons and so our experiments provide insights into the importance of type I interferon signalling and the consequences of its impairment on human NK cell biology. Surprisingly, the NK cells of these patients display essentially normal phenotype and function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Oncology, CNB-CSIC, Madrid, Spain.
- Immunology Department, University Hospital 12 de Octubre, Madrid, Spain.
- Hospital 12 Octubre Research Institute (Imas12), Madrid, Spain.
- Department of Immunology, La Paz University Hospital, Madrid, Spain.
- Immunodeficiency Unit, Department of Pediatrics, University Hospital 12 de Octubre, Madrid, Spain.
- School of Medicine, Complutense University of Madrid, Madrid, Spain.
ORCID-Profile: Luis Ignacio González-Granado, Luis M Allende, Hugh T Reyburn
Förderung
- Carlos III Health Institute
- Secretaría de Estado de Investigación, Desarrollo e Innovación
- Spanish Association Against Cancer
- Instituto de Salud Carlos III
Zitieren
APA
Calvo-Apalategi, A., Nevado, M. L., Bravo-Gallego, L. Y., González-Granado, L. I., Allende, L. M., Pena, R. R., López-Granados, E., & Reyburn, H. T. (2024). The lack of either IRF9 , or STAT2 , has surprisingly little effect on human natural killer cell development and function. Immunology. https://doi.org/10.1111/imm.13779
Vancouver
Calvo-Apalategi A, Nevado ML, Bravo-Gallego LY, González-Granado LI, Allende LM, Pena RR, et al. The lack of either IRF9 , or STAT2 , has surprisingly little effect on human natural killer cell development and function. Immunology. 2024. doi:10.1111/imm.13779
BibTeX
@article{CalvoApalategi2024,
author = {Calvo-Apalategi, Ane and Nevado, Marta López and Bravo-Gallego, Luz Yadira and González-Granado, Luis Ignacio and Allende, Luis M and Pena, Rebeca Rodríguez and López-Granados, Eduardo and Reyburn, Hugh T},
title = {The lack of either IRF9 , or STAT2 , has surprisingly little effect on human natural killer cell development and function},
journal = {Immunology},
year = {2024},
doi = {10.1111/imm.13779}
}
EUVIMED